ANI Pharmaceuticals Inc. ANIP

What this company does

ANI Pharmaceuticals develops, manufactures and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses. As of December 31, 2025, its Generics portfolio included more than 120 products with a wide variety of indications. As of January 2026, it had 970 employees, of whom 753 were in the U.S., 148 in India, 30 in the UK, 19 in Germany, 11 in Portugal, 8 in Ireland, and 1 in Canada. Its Cortrophin Gel is approved by the U.S. Food and Drug Administration for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis, in addition to excess urinary protein due to nephrotic syndrome. The Company markets ILUVIEN in the U.S. for chronic non-infectious uveitis affecting the posterior segment of the eye and for Diabetic Macular Edema, following a March 2025 FDA label expansion.

Written from the business description in ANI Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.